Bristol-Myers Squibb Hires Lobbyist on Health Issues

Bristol-Myers Squibb has engaged Alexander J. Beckles LLC to represent the company on health policy matters following a new lobbying disclosure filed in late June 2026. This move comes as the pharmaceutical giant faces increased scrutiny from lawmakers regarding its drug pricing practices and recent price hikes on key medications. The engagement signals a strategic effort by the company to navigate a complex regulatory environment and influence ongoing congressional debates over medical pricing.

Bristol-Myers Squibb Co. officially filed a lobbying disclosure on June 29, 2026, to enlist the services of Alexander J. Beckles LLC for representation on various health policy issues. Alex Beckles, the firm's principal, is designated as the sole lobbyist for this engagement. Beckles brings nearly eight years of Capitol Hill experience to the role, having previously served as a Senior Legislative Assistant to former Representative Edolphus Towns during the 106th through 110th Congresses. This hire marks a significant pivot for the pharmaceutical manufacturer as it seeks to bolster its presence in Washington amid intensifying legislative pressure.

The decision to hire external lobbying counsel follows public criticism regarding the company's pricing of Opdivo, a prominent cancer treatment. Since January 2025, Bristol-Myers Squibb has increased the price of Opdivo by 4%, bringing the cost to approximately $260,000. This pricing action occurred during the administration of President Donald Trump and has drawn the attention of lawmakers concerned about the rising costs of healthcare. In response to these pressures, the company has also entered into a "Most Favored Nation" agreement with the Trump Administration, a move shared by several other major players in the pharmaceutical industry.

This strategic engagement arrives at a critical time as Congress continues to examine the practices of the pharmaceutical sector, specifically focusing on medical pricing policies. By securing a former congressional staffer with deep legislative roots, Bristol-Myers Squibb aims to directly engage with lawmakers and shape the narrative surrounding drug pricing reform. The move highlights the broader industry trend of pharmaceutical companies intensifying their lobbying efforts to mitigate the impact of potential regulatory changes and to defend their pricing structures in a period of heightened government oversight.